Top

Published in:

Open Access 01-12-2017 | Research

The influence of dopamine-beta-hydroxylase and catechol O-methyltransferase gene polymorphism on the efficacy of insulin detemir therapy in patients with type 2 diabetes mellitus

Authors: Tomislav Bozek, Antonela Blazekovic, Matea Nikolac Perkovic, Kristina Gotovac Jercic, Aleksandra Sustar, Lea Smircic-Duvnjak, Tiago F. Outeiro, Nela Pivac, Fran Borovecki

Published in: Diabetology & Metabolic Syndrome | Issue 1/2017

Abstract

Background

Type II diabetes is an important health problem with a complex connection to obesity, leading to a broad range of cardiovascular complications. Insulin therapy often results in weight gain and does not always ensure adequate glycemic control. However, previous studies reported that insulin detemir is an efficient long-acting insulin with a weight sparing effect. The aim of this study was to determine the association of catechol O-methyltransferase (COMT) Val108/158Met and dopamine-beta-hydroxylase (DBH) 1021C/T polymorphisms with the effectiveness of insulin detemir in achieving glucose control and body weight control. Participants and methods: This 52-week observational study included 185 patients with inadequate glycemic control treated with premix insulin analogues, which were replaced with insulin aspart and insulin detemir, and 156 healthy controls. After DNA isolation from blood samples, genotyping of DBH-1021C/T polymorphism (rs1611115) and COMT Val108/158Met polymorphism (rs4680) was performed.

Results

Our results confirmed that insulin detemir did not lead to weight gain. The most significant finding was that A carriers (the combined AG and AA genotype) of the COMT Val108/158Met achieved significantly better hemoglobin A1c (HbA1c) values compared to patients carrying GG genotype. No association between DBH-1021C/T genotypes and weight and/or glucose control was detected in diabetes patients or in healthy control subjects.

Conclusions

This study showed that the presence of one or two A allele of the COMT Val108/158Met was associated with improved glycemic response, and with a better response to insulin detemir therapy in patients with type II diabetes, separating them as best candidates for detemir therapy.

Available only for authorised users

de Pablos-Velasco P, Bradley C, Eschwège E, Gönder-Frederick LA, Parhofer KG, Vandenberghe H, et al. The PANORAMA pan-European survey: glycaemic control and treatment patterns in patients with type 2 diabetes [Abstract 1012]. Diabetologia. 2010;53(Supplement 1):S405.

Liebl A, Mata M, Eschwège E. Evaluation of risk factors for development of complications in type II diabetes in Europe. Diabetologia. 2002;45(7):23–8. https://doi.org/10.1007/s00125-002-0863-0.CrossRef

Johnson WD, Krown JL, Greenway FL, Bouchard C, Ryan D, Katzmarzyk PT. Prevalence of risk factors for metabolic syndrome in adolescents: national Health and Nutrition Examination Survey (NHANES), 2001–2006. Arch Pediatr Adolesc Med. 2009;163:371–7. https://doi.org/10.1001/archpediatrics.2009.3.CrossRefPubMed

Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006;444(7121):840–6. https://doi.org/10.1038/nature05482.CrossRefPubMed

Norris SL, Zhang X, Avenell A, et al. Long-term effectiveness of lifestyle and behavioral weight loss interventions in adults with type 2 diabetes: a meta-analysis. Am J Med. 2004;117:762–74. https://doi.org/10.1016/j.amjmed.2004.05.024.CrossRefPubMed

Eeg-Olofsson K, Cederholm J, Nilsson PM, et al. Risk of cardiovascular disease and mortality in overweight and obese patients with type 2 diabetes: an observational study in 13,087 patients. Diabetologia. 2009;52:65–73. https://doi.org/10.1007/s00125-008-1190-x.CrossRefPubMed

Martyn JA, Kaneki M, Yasuhara S. Obesity-induced insulin resistance and hyperglycemia: etiologic factors and molecular mechanisms. Anesthesiology. 2008;109(1):137–48. https://doi.org/10.1097/ALN.0b013e3181799d45.CrossRefPubMed

Sandoval D, Cota D, Seeley RJ. The integrative role of CNS fuel-sensing mechanisms in energy balance and glucose regulation. Annu Rev Physiol. 2008;70:513–35. https://doi.org/10.1146/annurev.physiol.70.120806.095256.CrossRefPubMed

Schwartz MW, Woods SC, Porte D Jr, Seeley RJ, Baskin DG. Central nervous system control of food intake. Nature. 2000;404:661–71. https://doi.org/10.1038/35007534.CrossRefPubMed

10.

Cubells JF, van Kammen DP, Kelley ME, et al. Dopamine beta-hydroxylase: two polymorphisms in linkage disequilibrium at the structural gene DBH associate with biochemical phenotypic variation. Hum Genet. 1998;102(5):533–40.CrossRefPubMed

11.

Zabetian CP, Anderson GM, Buxbaum SG, et al. A quantitative- trail analysis of human plasma- dopamine beta- hydroxylase activity: evidence for major functional polymorphism at the DBH locus. Am J Hum Genet. 2001;68:515–22. https://doi.org/10.1086/318198.CrossRefPubMedPubMedCentral

12.

Mustapic M, Presecki P, Pivac N, Mimica N, Hof PR, Simic G, Folnegovic-Smalc V, Muck-Seler D. Genotype-independent decrease in plasma dopamine beta-hydroxylase activity in Alzheimer’s disease. Progr Neuro-Psychopharmacol Biol Psychiatry. 2013;44:84–99. https://doi.org/10.1016/j.pnpbp.2013.02.002.CrossRef

13.

Azevedo MS, Fernandes FF, Lisboa P, Manso C. Relationship between the activity of plasma dopamine-beta-hydroxylase and the duration of diabetes mellitus. Acta Med Port. 1983;4(9–10):387–9.PubMed

14.

Ste Marie L, Palmiter RD. Norepinephrine and epinephrine-deficient mice are hyperinsulinemic and have lower blood glucose. Endocrinology. 2003;144:4427–32.CrossRefPubMed

15.

Creveling CR. The role of catechol-O-methyltransferase in the inactivation of catecholestrogen. Cell Mol Neurobiol. 2003;23:289–91.CrossRefPubMed

16.

Halford JC, Cooper GD, Dovey TM. The pharmacology of human appetite expression. Curr Drug Targets. 2004;5:221–40.CrossRefPubMed

17.

Wang SS, Morton LM, Bergen AW, et al. Genetic variation in catechol-O-methyltransferase (COMT) and obesity in the prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial. Hum Genet. 2007;122(1):41–9. https://doi.org/10.1007/s00439-007-0374-7.CrossRefPubMed

18.

Nedić G, Nikolac M, Nenadic Sviglin K, Muck-Šeler D, Borovečki F, Pivac N. Association study of functional catechol-O-methyltransferase (COMT) Val 108/158 Met polymorphism and suicide attempts in patients with alcohol dependence. Int J Neuropsychopharmacol. 2011;14:377–88. https://doi.org/10.1017/S1461145710001057.CrossRefPubMed

19.

Nedić G, Borovečki F, Klepac N, Mubrin Z, Hajnšek S, Nikolac M, Muck-Šeler D, Pivac N. Association study of a functional catechol-O-methyltransferase polymorphism and cognitive function in patients with dementia. Coll Antropol. 2011;35(Suppl 1):79–84.PubMed

20.

Malhotra AK, Lencz T, Correll CU, Kane JM. Genomics and the future of pharmacotherapy in psychiatry. Int Rev Psychiatry. 2007;19(5):523–30. https://doi.org/10.1080/09540260701563460.CrossRefPubMed

21.

Mannisto PT, Kaakkola S. Catechol-O- methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev. 1999;51(4):593–628.PubMed

22.

Nedic Erjavec G, Nenadic Sviglin K, Nikolac Perkovic M, Muck-Seler D, Jovanovic T, Pivac N. Association of gene polymorphisms encoding dopaminergic system components and platelet MAO-B activity with alcohol dependence and alcohol dependence-related phenotypes. Progr Neuro-Psychopharmacol Biol Psychiatry. 2014;54:321–7. https://doi.org/10.1016/j.pnpbp.2014.07.002.CrossRef

23.

Lachman HL, Papolos D, Saito T, Yu YM, Szumlanski CL, Weinshilboum RM. Human catechol-O-methyltransferase pharmacogenetics:description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics. 1996;6:243–50.CrossRefPubMed

24.

Lotta T, Vidgren J, Tilgmann C, Ulmanen I, Melén K, Julkunen I, Taskinen J. Kinetics of human soluble and membrane-bound catechol-O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Byochemistry. 1995;34:4202–10.CrossRef

25.

Chen J, Lipska BK, Halim N, Ma QD, Matsumoto M, Melhem S, et al. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am J Hum Genet. 2004;75:807–21. https://doi.org/10.1086/425589.CrossRefPubMedPubMedCentral

26.

González-Castro TB, Hernández-Díaz Y, Juárez-Rojop IE, López-Narváez ML, Tovilla-Zárate CA, Fresan A. The role of a catechol-O-methyltransferase (COMT) Val158Met genetic polymorphism in schizophrenia: a systematic review and updated meta-analysis on 32,816 subjects. Neuromol Med. 2016;18(2):216–31. https://doi.org/10.1007/s12017-016-8392-z.CrossRef

27.

Annerbrink K, Westberg L, Nilsson S, Rosmond R, Holm G, Eriksson E. Catechol O-methyltransferase val158-met polymorphism is associated with abdominal obesity and blood pressure in men. Metab Clin Exp. 2008;57:708–11. https://doi.org/10.1016/j.metabol.2008.01.012.CrossRefPubMed

28.

Kamide K, Kokubo Y, Yang J, Matayoshi T, Inamoto N, Takiuchi S, et al. Association of genetic polymorphisms of ACADSB and COMT with human hypertension. J Hypertens. 2007;25(1):103–10. https://doi.org/10.1097/HJH.0b013e3280103a40.CrossRefPubMed

29.

Kring SI, Werge T, Holst C, Toubro S, Astrup A, Hansen T, Pedersen O, Sørensen TI. Polymorphisms of serotonin receptor 2A and 2C genes and COMT in relation to obesity and type 2 diabetes. PLoS ONE. 2009;4(8):e6696. https://doi.org/10.1371/journal.pone.0006696.CrossRefPubMedPubMedCentral

30.

Nathan DM. Finding new treatment for diabetes-how many, how fast… how good? N Eng J Med. 2007;356:437–40. https://doi.org/10.1056/NEJMp068294.CrossRef

31.

Heise T, Nosek L, Ronn BB, Endahl L, Heinemann L, Kapitza C, Draeger E. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes. 2004;53:1614–20 PMID: 15161770.CrossRefPubMed

32.

Hallschimd M, Jauch-Chara K, Korn O, Mölle M, Rasch B, Born J, Schultes B, Kern W. Euglycemic infusion of insulin Detemir Compared with human insulin appears to increase direct current brain potential response and reduces food intake while inducing similar systemic effects. Diabetes. 2010;59:1101–7. https://doi.org/10.2337/db09-1493.CrossRef

33.

Russell-Jones D, Danne T, Hermansen K, Niswender K, Robertson K, Thalange N, Vasselli JR, Yildiz B, Häring HU. Weight-sparing effect of insulin detemir: a consequences of central nervous system-mediated reduced energy intake? Diabetes Obes Metab. 2015;17:919–27. https://doi.org/10.1111/dom.12493.CrossRefPubMedPubMedCentral

34.

Zacharian S, Sheldon B, Shojaee-Moradie F, Jackson NC, Backhouse K, Johnsen S, Jones RH, Umpleby AM, Russell-Jones DL. Insulin Detemir reduces weight gain as a result of reduced food intake in patient with type 1 Diabetes. Diabetes Care. 2011;34:1487–91. https://doi.org/10.2337/dc11-0098.CrossRef

35.

American Diabetes Association. Standards of medical care. Diabetes Care. 2015;38(Supplement 1):S1–2. https://doi.org/10.2337/dc15-S001.

36.

Xiu L, Lin M, Liu W, Kong D, Liu Z, Zhang Y, et al. Association of DRD3, COMT, and SLC6A4 gene polymorphisms with type 2 diabetes in southern Chinese: a hospital-based case–control study. Diabetes Technol Ther. 2015;17(8):580–6. https://doi.org/10.1089/dia.2014.0344.CrossRefPubMed

37.

Barrie ES, Weinshenker D, Verma A, Pendergrass SA, Lange LA, Ritchie MD, et al. Regulatory polymorphisms in human DBH affect peripheral gene expression and sympathetic activity. Circ Res. 2014;115(12):1017–25. https://doi.org/10.1161/CIRCRESAHA.116.304398.CrossRefPubMedPubMedCentral

38.

Fox CS. Cardiovascular disease risk factors, type 2 diabetes mellitus, and the Framingham Heart Study. Trends Cardiovasc Med. 2010;20(3):90–5. https://doi.org/10.1016/j.tcm.2010.08.001.CrossRefPubMedPubMedCentral

39.

Peppa M, Uribarri J, Vlassara H. Glucose, advanced glycation end products, and diabetes complications: what is new and what works. Clin Diabetes. 2003;21(4):186–7. https://doi.org/10.2337/diaclin.21.4.186.CrossRef

40.

Vicente Miranda H, Szego ÉM, Oliveira LMA, Breda C, Darendelioglu E, de Oliveira RM, et al. Glycation potentiates α-synuclein-associated neurodegeneration in synucleinopathies. Brain. 2017;140(5):1399–419. https://doi.org/10.1093/brain/awx056.CrossRefPubMed

41.

Schernthaner G, Currie CJ, Schernthaner GH. Do we still need pioglitazone for the treatment of type 2 diabetes? a risk-benefit critique in 2013. Diabetes Care. 2013;36(Supplement 2):155–61. https://doi.org/10.2337/dcS13-2031.CrossRef

42.

Juutilainen A, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Similarity of the impact of type 1 and type 2 diabetes on cardiovascular mortality in middle aged subjects. Diabetes Care. 2008;31:714–9. https://doi.org/10.2337/dc07-2124.CrossRefPubMed

43.

Schernthaner G, Currie CJ, Schernthaner GH. Do we still need pioglitazone for the treatment of type 2 diabetes? A risk-benefit critique in 2013. Diabetes Care. 2013;36(Suppl 2):S155–61. https://doi.org/10.2337/dcS13-2031.CrossRefPubMedPubMedCentral

44.

Fujioka K. Benefits of moderate weight loss in patients with type 2 diabetes. Diabetes Obes Metab. 2010;12(3):186–94. https://doi.org/10.1111/j.1463-1326.2009.01155.x.CrossRefPubMed

45.

Zafar MI, Hu C, Liu D, Shafqat RA, Gao F. Insulin Detemir causes lesser weight gain in comparison to insulin glargine: role on hypothalamic NPY and galanin. J Diabetes Res. 2014;2014:458104.CrossRefPubMedPubMedCentral

46.

Kathiresan S, Srivastava D. Genet Hum Cardiovasc Dis. Cell. 2012;148(6):1242–57. https://doi.org/10.1016/j.cell.2012.03.001.CrossRefPubMedPubMedCentral

47.

Hall KT, Nelson CP, Davis RB, Buring JE, Kirsch I, Mittleman MA, et al. Polymorphisms in catechol-O-methyltransferase modify treatment effects of aspirin on risk of cardiovascular disease. Arterioscler Thromb Vasc Biol. 2014;34(9):2160–7. https://doi.org/10.1161/ATVBAHA.114.303845.CrossRefPubMedPubMedCentral

48.

Need AC, Ahmadi KR, Spector TD, Goldstein DB. Obesity is associated with genetic variants that alter dopamine availability. Ann Hum Genet. 2006;70(3):293–303. https://doi.org/10.1111/j.1529-8817.2005.00228.x.CrossRefPubMed

49.

Tworoger SS, Chubak J, Aiello EJ, Yasui Y, Ulrich CM, Farin FM, et al. The effect of CYP19 and COMT polymorphisms on exercise-induced fat loss in postmenopausal women. Obes Res. 2004;12(6):972–81. https://doi.org/10.1038/oby.2004.119.CrossRefPubMed

50.

Hall KT, Jablonski KA, Chen L, Harden M, Tolkin BR, Kaptchuk TJ, Bray GA, Ridker PM, Florez JC, Diabetes Prevention Program Research Group, Mukamal KJ, Chasman DI. Catechol-O-methyltransferase association with hemoglobin A1c. Metabolism. 2016;65(7):961–7. https://doi.org/10.1016/j.metabol.2016.04.001.CrossRefPubMedPubMedCentral

51.

Wessel J, Moratorio G, Rao F, Mahata M, Zhang L, Greene W, et al. C-reactive protein, an ‘intermediate phenotype’ for inflammation: human twin studies reveal heritability, association with blood pressure and the metabolic syndrome, and the influence of common polymorphism at catecholaminergic/beta-adrenergic pathway loci. J Hypertens. 2007;25(2):329–43. https://doi.org/10.1097/HJH.0b013e328011753e.CrossRefPubMed

52.

Arnold AC, Garland EM, Celedonio JE, Raj SR, Abumrad NN, Biaggioni I, et al. Hyperinsulinemia and insulin resistance in dopamine β-hydroxylase deficiency. J Clin Endocrinol Metab. 2017;102(1):10–4. https://doi.org/10.1210/jc.2016-3274.PubMed

53.

Xie T, Ho SL, Ramsden D. Characterization and implications of estrogenic down-regulation of human catechol-O-methyltransferase gene transcription. Mol Pharmacol. 1999;56:31–8.PubMed

54.

Nikolac M, Sagud M, Nedic G, Nenadic Sviglin K, Mihaljevic Peles A, Uzun S, Vuskan Cusa B, Kozumplik O, Zivkovic M, Mustapic M, Jakovljevic M, Pavlovic M, Muck-Seler D, Borovecki F, Pivac N. The lack of association between catechol-O-methyl-transferase Val108/158Met polymorphism and smoking in schizophrenia and alcohol dependence. Letter to the Editor. Psychiatry Res. 2013;205:179–80. https://doi.org/10.1016/j.psychres.2012.08.001.CrossRefPubMed

55.

Zilov A, El Naggar N, Shah S, Shen C, Haddad J. Insulin detemir in the management of type 2 diabetes in non-Western countries: safety and effectiveness data from the Archieve observational study. Diabetes Res Clin Pract. 2013;101(3):317–25. https://doi.org/10.1016/j.diabres.2013.06.003.CrossRefPubMed

Title: The influence of dopamine-beta-hydroxylase and catechol O-methyltransferase gene polymorphism on the efficacy of insulin detemir therapy in patients with type 2 diabetes mellitus
Authors: Tomislav Bozek
Antonela Blazekovic
Matea Nikolac Perkovic
Kristina Gotovac Jercic
Aleksandra Sustar
Lea Smircic-Duvnjak
Tiago F. Outeiro
Nela Pivac
Fran Borovecki
Publication date: 01-12-2017
Publisher: BioMed Central
Published in: Diabetology & Metabolic Syndrome / Issue 1/2017
Electronic ISSN: 1758-5996
DOI: https://doi.org/10.1186/s13098-017-0295-0

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

The influence of dopamine-beta-hydroxylase and catechol O-methyltransferase gene polymorphism on the efficacy of insulin detemir therapy in patients with type 2 diabetes mellitus

Abstract

Background

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2017

Association between aerobic capacity and the improvement in glycemic control after the exercise training in type 2 diabetes

Educ@dom: comparative study of the telemonitoring of patients with type 2 diabetes versus standard monitoring—study protocol for a randomized controlled study

Analysis of factors influencing glucose tolerance in Japanese patients with non-alcoholic fatty liver disease

Long-term feeding of high-fat plus high-fructose diet induces isolated impaired glucose tolerance and skeletal muscle insulin resistance in miniature pigs

The waist circumference-adjusted associations between hyperuricemia and other lifestyle-related diseases

Mesenchymal stem cell therapy in type 2 diabetes mellitus

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page